Iconovo AB (publ) (ICO.ST) Stock Analysis & Winston Score

Iconovo is a small Swedish company that helps other pharmaceutical companies develop and manufacture inhalers — the devices people use to breathe in medicine for conditions like asthma and COPD. Its main product is a family of ready-to-use inhaler platforms, including the ICOone and ICOcap devices, which drug companies can license and fill with their own medicines instead of building an inhaler from scratch. The company operates in the medical device and drug delivery industry, focused entirely on inhaled therapies. Iconovo makes money by licensing its inhaler designs to pharmaceutical partners and charging fees for development services and manufacturing. It is based in Lund, Sweden, and operates primarily in Europe, though it targets global pharma clients. The company is very small and not yet profitable, as shown by its deeply negative margins, meaning it spends far more than it earns today. The key growth driver is signing new licensing deals with drug companies, but the main risk is that it may need to raise more cash before it reaches a sustainable revenue base.